Heron Therapeutics, Inc. reported a net loss of $20.2 million for the fiscal year ending December 31, 2025, compared to a net loss of $13.6 million in the previous year. The company's total revenue from product sales reached $154.9 million, marking a 7.4% increase from $144.3 million in 2024. This growth was primarily driven by a significant 65.1% increase in acute care product sales, particularly for ZYNRELEF and APONVIE, while oncology product sales saw a decline of 7.8%, largely due to increased gross-to-net adjustments and a decrease in SUSTOL units sold.

The cost of product sales increased by 7.0% to $41.3 million, reflecting higher unit sales and increased inventory reserves. Operating expenses decreased slightly to $116.1 million from $117.2 million in 2024, with research and development expenses dropping significantly by 25.5% to $12.4 million, attributed to reduced personnel costs following a restructuring in 2023. General and administrative expenses rose marginally, while sales and marketing expenses increased by 4.2% due to heightened marketing efforts for ZYNRELEF.

Strategically, Heron entered a co-promotion agreement with Crosslink Network in January 2024 to enhance the promotion of ZYNRELEF for orthopedic indications. The company also made significant changes to its executive leadership structure in 2023, which included severance payments and stock award modifications totaling $13.4 million. As of December 31, 2025, Heron employed 128 full-time staff, with 78 in sales and marketing roles.

Looking ahead, Heron anticipates that its existing cash, cash equivalents, and short-term investments of $46.6 million will be sufficient to meet its operational needs for at least the next year. The company is also focused on managing its inventory and production costs while navigating the competitive landscape of the biotechnology sector, which includes ongoing litigation related to its product patents. The company intends to continue enforcing its intellectual property rights vigorously, particularly concerning its CINVANTI product, as it faces challenges from generic competitors.

About HERON THERAPEUTICS, INC. /DE/

Heron Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for acute care and oncology patients. Its portfolio includes products like ZYNRELEF for postoperative pain, APONVIE for nausea, and antiemetics CINVANTI and SUSTOL. The company leverages proprietary drug delivery technology, operates in regulated markets, and relies on third-party manufacturing and patent protections to maintain its competitive position.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.